Why the study?
To compare the performance of pulmonary homografts with stentless bioprosthetic valves in the pulmonary position in patients with congenital heart disease younger than 20 years.
Do stentless bioprosthetic valves compared to pulmonary homografts improve freedom from reintervention and structural valve degeneration in patients younger than 20 years with congenital heart disease?
Population
215 CHD patients younger than 20 years across 3 centres in Australia
Comparison
Pulmonary homografts vs Medtronic Freestyle stentless bioprosthetic valves
Design
Multicentre retrospective propensity-matched cohort study
Authors
Loading...
Freestyle valves associated with higher late reintervention risk in young CHD patients; leaves open optimal choice in prospective trials.
Do stentless bioprosthetic valves compared to pulmonary homografts improve freedom from reintervention and structural valve degeneration in patients younger than 20 years with congenital heart disease?
Stentless bioprosthetic valves are a comparable alternative to pulmonary homografts for up to 10 years in pediatric and young adult patients, but are associated with significantly higher rates of reintervention and structural degeneration thereafter.
Marathe et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: